Efficacy and safety of topical tazarotene: A review

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 2, 2009, Pages 195-210

  Talpur, Rakhashandra ^a   Cox, Katherine ^a   Duvic, Madeleine ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Acne; Actinic damage; Efficacy; Psoriasis; Retinoid; Tazarotene

Indexed keywords

ADALIMUMAB; ADAPALENE; ALEFACEPT; ALITRETINOIN; ALTINAC; ATRALIN; BEXAROTENE; CALCIPOTRIOL; CLINDAMYCIN; CLOBETASOL BUTYRATE; CLOBETASOL PROPIONATE; CYCLOSPORIN; DIFLORASONE DIACETATE; DOXYCYCLINE; EFALIZUMAB; ETANERCEPT; ETRETIN; FLUOCINOLONE ACETONIDE; FLUOCINONIDE; FLUTICASONE PROPIONATE; HYDROQUINONE; INFLIXIMAB; ISOTRETINOIN; LIAROZOLE; METHOTREXATE; METRONIDAZOLE; MINOCYCLINE; MOMETASONE FUROATE; RETINOIC ACID; RETINOID; RETINOL; TAZAROTENE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACNE; ACNE VULGARIS; ACTINIC KERATOSIS; ACTINIC POROKERATOSIS; ADD ON THERAPY; ADJUVANT THERAPY; ALOPECIA AREATA; ANTIINFLAMMATORY ACTIVITY; BASAL CELL CARCINOMA; BURNING SENSATION; CARCINOMA IN SITU; CHEMOSURGERY; CLINICAL TRIAL; COMPARATIVE STUDY; CRYOSURGERY; CUTANEOUS T CELL LYMPHOMA; CYST; DARIER DISEASE; DERMATITIS; DESQUAMATION; DISSEMINATED SUPERFICIAL ACTINIC POROKERATOSIS; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; DRY SKIN; DYSKERATOSIS; ELASTOSIS; ERYTHEMA; ERYTHROKERATODERMA FIGURATA VARIABILIS; EVENING DOSAGE; GENE EXPRESSION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERPIGMENTATION; HYPERTRIGLYCERIDEMIA; HYPOPIGMENTATION; HYPOTHYROIDISM; ICHTHYOSIS; KAPOSI SARCOMA; KERATINIZATION; KERATOSIS; KERATOSIS PILARIS; LENTIGINOSIS; LENTIGO; MONOTHERAPY; MYCOSIS FUNGOIDES; NAIL DYSTROPHY; NEUROBLASTOMA; NEUROPATHY; OCCUPATIONAL KOILONYCHIA; PAPULE; PHOTOAGING; PHOTOTHERAPY; PITYRIASIS RUBRA PILARIS; POSTINFLAMMATORY HYPERPIGMENTATION; POSTMARKETING SURVEILLANCE; PREGNANCY TERMINATION; PRURITUS; PSORIASIS; PSORIASIS VULGARIS; PUSTULE; PYOGENIC GRANULOMA; RECOMMENDED DRUG DOSE; REVIEW; ROSACEA; SHELF LIFE; SIDE EFFECT; SINGLE DRUG DOSE; SKIN CANCER; SKIN DISEASE; SKIN IRRITATION; SKINFOLD THICKNESS; SQUAMOUS CELL CARCINOMA; STRATUM CORNEUM; TELANGIECTASIA; TOPICAL TREATMENT; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; WRINKLE; XEROSIS;

ACNE VULGARIS; ADMINISTRATION, CUTANEOUS; ANIMALS; CARCINOMA, BASAL CELL; DERMATOLOGIC AGENTS; HUMANS; NICOTINIC ACIDS; PSORIASIS; RECEPTORS, RETINOIC ACID; SKIN AGING; UP-REGULATION;

EID: 67649086703     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250902721250     Document Type: Review

References (118)

1. Cheng C, Michaels J, Scheinfeld N. Alitretinoin: a comprehensive review. Expert Opin Investig Drugs 2008;17(3):437-443
2. Nagpal S, Chandraratna RA. Recent developments in receptor-selective retinoids. Curr Pharm Des 2000;6:919-931 (Pubitemid 30409389)
3. Germain P, Chambon P, Eichele G, et al. International union of Pharmacology. LXIII. Retinoid X receptors. Pharmacol Rev 2006;58:760-772
4. Germain P, Chambon P, Eichele G, et al. International union of Pharmacology. LX. Retinoid X receptors. Pharmacol Rev 2006;58:712-725
5. Chandraratna RA. Tazarotene - first of a new generation of receptor-selective retinoids. Br J Dermatol 1996;135(49):18-25 (Pubitemid 126833473)
6. Duvic M, Helekar B, Schulz C, et al. Expression of a retinoid-inducible tumor suppressor, Tazarotene-inducible gene-3, is decreased in psoriasis and skin cancer. Clin Cancer Res 2000;6(8):3249-59 • Intresting article on the expression of retinoid inducible tumor suppressor that tazarotene inducible gene-3 (TIG-3) is significantly decreased in psoriasis and squamous and basal cell carcinomas when compared with the adjacent normal skin.
7. Peris K, Fargnoli MC, Chimenti S. Preliminary observations on the use of topical tazarotene to treat basal cell carcinoma. N Engl J Med 1999;341(23):1767-1768
8. Apisarnthanarax N, Talpur R, Duvic M. Treatment of cutaneous T cell lymphoma: current status and future directions. Am J Clin Dermatol 2002;3(3):193-215 (Pubitemid 34533779)
9. Thiboutot DM, Shalita AR, Yamauchi PS, et al. Combination therapy with adapalene gel 0.1% and doxycycline for severe acne vulgaris: a multicenter, investigator-blind, randomized, controlled study. Skin Med 2005;4:138-146
10. Altinyazar HC, Koca R, Tekin NS, et al. Adapalene vs. metronidazole gel for the treatment of rosacea. Int J Dermatol 2005;44:252-255 (Pubitemid 40425677)
11. Pariser DM, Thiboutot DM, Clark SD, et al. The efficacy and safety of adapalene gel 0.3% in the treatment of acne vulgaris: a randomized, multicenter, investigator-blinded, controlled comparison study versus adapalene gel 0.1% and vehicle. Cutis 2005;76:145-151 (Pubitemid 41290901)
12. Bassiri-Tehrani S, Cohen DE. Treatment of cutaneous T-cell lymphoma with alitretinoin gel. Int J Dermatol 2002;41:104-106 (Pubitemid 34552358)
13. Duvic M, Friedman-Kein AE, Galpin J, et al. Phase I-II clinical trial support safety and efficacy of ALRT 1057 Topical retinoid gel for Kaposi sarcoma. Submitted XI International Conference on AIDS. 1996
14. Maloney DM, Schmidt JD, Duvic M. Alitretinoin gel to treat pyogenic granuloma. J Am Acad Dermatol 2002;47(6):969-977 (Pubitemid 35403069)
15. Baumann L, Vujevich J, Halem M, et al. Open-label pilot study of alitretinoin gel 0.1% in the treatment of photoaging. Cutis 2005;76:69-73 (Pubitemid 41097504)
16. Reynolds CP, Lemons RS. Retinoid therapy of childhood cancer. Hematol Oncol Clin North Am 2001;15:867-910 (Pubitemid 34026975)
17. Duvic M, Apisarnthanarax N, Cohen DS. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2003;49(1):35-49 (Pubitemid 36801629)
18. Taylor PW, Keenan MH. Pharmaceutical quality of generic isotretinoin products, compared with Roaccutane. Curr Med Res Opin 2006;22:603-615
19. Zhang C, Hazarika P, Ni X, et al. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002:8:1234-1240 (Pubitemid 34517663)
20. Smit JV, Franssen ME, de Jong EM, et al. A phase II multicenter clinical trial of systemic bexarotene in psoriasis. J Am Acad Dermatol 2004;51:249-256
21. Smit JV, de Jong EM, van Hooijdonk CA, et al. Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation, and improves differentiation in lesional skin. J Am Acad Dermatol 2004;51:257-264
22. Hanifin JM, Stevens V, Sheth P, et al. Novel treatment of chronic severe hand dermatitis with bexarotene gel. Br J Dermatol 2004;150:545-553 (Pubitemid 38446312)
23. Talpur R, Vu J, Bassett R, et al. Phase I/II Randomized Bilateral Half-Head Comparison of Topical Bexarotene 1% Gel for Alopecia Areata. Unpublished data
24. Dockx P, Decree J, Degreef H. Inhibition of the metabolism of endogenous retinoic acid as treatment for severe psoriasis: an open study with oral liarozole. Br J Dermatol 1995;133:426-432
25. Vahlquist A, Duvic M. Retinoids and carotenoids in dermatology. first edition. Informa Healthcare; 2007
26. Tang-Liu DD, Matsumoto RM, Usansky JI. Clinical pharmacokinetics and drug metabolism of tazarotene: a novel topical treatment for acne and psoriasis. Clin Pharmacokinet 1999;37(4):273-287 (Pubitemid 29515694)
27. Weinstein GD, Krueger GG, Lowe NJ, et al. Tazarotene gel a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol 1997;37:85-92 (Pubitemid 27287698)
28. Shalita AR, Chalker DK, Griffith RF, et al. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double blind, vehicle controlled study. Cutis 1999;63:349-354
29. Chen DS, Sandri RB, Tang Liu DDS. Systemic pharmacokinetics of acitretin, etretinate, isotretinoin, and acetylenic retinoids in guinea pigs and obese rats. Drug Metab Disp 1992;20:211-217
30. Lippman SM, Glisson BS, Kavanagh JJ, et al. Retinoic acid and interferon combination studies in human cancer. Eur J Cancer 1993;29A (Suppl 5):S9-13 (Pubitemid 23293863)
31. DiSepio D, Ghosn C, Eckert RL, et al. Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene. Proc Natl Acad Sci USA 1998;95(25):14811-14815 (Pubitemid 29003712)
32. Duvic M. Tazarotene: a review of its pharmacological profile. Exp opin invest Drugs 1997;6(10):1573-1651
33. Study report PK-1989-2032 Transdermal permeation, disposition and bioconversion of SKF 190168 from one gel formulation using human fresh skin, human cadaver skin and fuzzy rat skin as skin barrier. Irvine (CA):Allergan, 1989
34. 14C-AGN 190168 0.1% gel following topical administration to healthy subjects (clinical study R168-150-7997). Irvine (CA):Allergan, 1993
35. Franz TJ, Lehman PA, Franz SL, et al. Percutaneous absorption of AGN 190168, a new synthetic retinoid, through human skin in vivo. J Invest Dermatol 1992;98:650
36. Kruger JG. The immunologic basis for the treatment of psoriasis with the new biologic agents. J Am Acad Dermatol 2002;46:1-23 (Pubitemid 34073472)
37. Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004;9(2):136-139 (Pubitemid 38457271)
38. Kenney JA. Psoriasis in the American black. In: Farber EM, Cox AJ, editors, Psoriasis: proceedings of the International Symposium, Stanford University. Stanford, Calif.: Stanford University Press, 1971. p. 49-52
39. Christophers E. Psoriasis- epidemiology and clinical spectrum. Clin Exp Dermatol 2001;26:314-320 (Pubitemid 34204344)
40. Thaci D. Long-term data in the treatment of psoriasis. Br J Dermatol 2008;159(2):18-24
41. Weinstein GD, Krueger GG, Lowe NJ, et al. Tazarotene gel, a new retionid for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect. J Am Acad Dermatol 1997;37:85-92 • The study demonstrates the safety and efficacy of tazarotene gel for psoriasis.
42. Weinstein GD, Koo JY, Krueger GG, et al. Tazarotene cream in the treatment of psoriasis: two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol 2003;48(5):760-7 • The study is about the safety and efficacy of tazarotene cream in psoriasis. (Pubitemid 36583288)
43. Krueger GG, Drake LA, Elias PM, et al. The safety and efficacy of tazarotene gel a topical acetylenic retinoid, in the treatment of psoriasis. Arch Dermatol 1998;134:57-60 (Pubitemid 28087114)
44. Lebwohl M, Ast E, Callen J, et al. Once daily tazarotene gel versus twice daily floucinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998;38:705-711 (Pubitemid 28213714)
45. Guenther L. Tazarotene combination treatment in psoriasis. J Am Acad Dermatol 2000;43:S31-S35
46. Koo JY, Martin D. Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis. Int J Dermatol 2001;40:210-212 (Pubitemid 32586285)
47. Guenther LC, Poulin YP, Pariser DM. A comparison of tazarotene 0.1% gel once daily plus mometasone furoate 0.1% cream once daily versus calcipotriene 0.005% ointment twice daily in the treatment of plaque psoriasis. Clin Ther 2000;22:1225-1238 (Pubitemid 30809730)
48. Behrens S, Grundmann-Kollman M, Schiener R, Peter Ru Kerscher M. Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel. J Am Acad Dermatol 2000;42:493-495 (Pubitemid 30470360)
49. Gollnick H, Menter A. A combination therapy with tazarotene plus a topical corticosteroid for the treatment of plaque psoriasis. Br J Dermatol 1999;40(54):18-23 (Pubitemid 29191433)
50. Lebwohl M, Lombardi K, Tan MH. Duration of improvement in psoriasis after treatment with tazarotene 0.1% gel plus clobetasol propionate 0.05% ointment; comparison of maintenance treatments. Int J Dermatol 2001;40:64-66 (Pubitemid 32201237)
51. Green L, Sadoff W, Lebwohl MG, et al. A clinical evaluation of tazarotene 0.1% gel with and without a high- or mid-high-potency corticosteroid, in patients with stable plaque psoriasis. J Cutan Med Surg 2002;30:95-102 (Pubitemid 34563761)
52. Lebwohl MG, Breneman DL, Goffe BS, et al. Tazarotene 0.1% gel plus corticosteroid cream in the treatment of plaques psoriasis. J Am Acad Dermatol 1998;39:590-596 (Pubitemid 28465882)
53. Bowman PH, Maloney JE, Koo JY. Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study. J Am Acad Dermatol 2002;46:907-913
54. Stuttgen G. Zur Lokal behandlung von keratosen mit Vitamin A-Säure. Dermatologica 1962;124:65-80
55. Saurat JH, Hirschel-Scholz S, Salomon D. Human skin retinoid-binding proteins and therapy with synthetic retinoids: a still unexplained link. Dermatologica 1987;175(1):13-19 (Pubitemid 17164509)
56. Tanghetti E, Abramovits W, Solomon B, et al. Tazarotene versus Tazarotene plus Clindamycin/Benzoyl Peroxide in the Treatment of Acne Vulgaris: A Multicenter, Double-Blind Randomized Parallel-Group Trial. J Drugs Dermatol 2006;5(3):256-261
57. Shalita AR, Berson DS, Thiboutot DM, et al. Effects of Tazarotene 0.1% Cream in the Treatment of Facial Acne Vulgaris: Pooled Results from Two Multicenter, Double-blind, Randomized, Vehicle-Controlled, Parallel-Group Trials. Clin Ther 2004;26(11):1865-1873 (Pubitemid 40089499)
58. Wauben-Penris PJ, Cerneus DP, van den Hoven WE, et al. Immunomodulatory effects of tretinoin in combination with clindamycin. J Eur Acad Dermatol Venereol 1998;11(Suppl 1):S2-7; discussion S28-9 (Pubitemid 29005191)
59. Rigopoulos D, Ioannides D, Kalogeromitros D, Katsambas AD. Comparison of Topical Retinoids in the Treatment of Acne. J Clin Dermatol 2004;22:408-411 (Pubitemid 39535283)
60. Guenther LC. Optimizing treatment with topical tazarotene. Am J Clin Dermatol 2003;4:197-202 (Pubitemid 36390476)
61. Thielitz A, Naser MB, Fluhr JW, et al. Topical Retinoids in Acne - an Evidence-based overview. J Dtsch Dermatol Ges 2008;6
62. Pariser D, Colon L, Johnson L, Gottschalk R. Adapalene 0.1% gel compared to tazarotene 0.1% cream in the treatment of acne vulgaris. J Drug Dermatol 2008;7(6):S18(6)
63. Kakita L. Tazarotene versus tretinoin or adalpane in the treatment of acne vulgaris. Presented at the Symposium "New directions in the treatment of psoriasis, acne, and skin aging." J Am Acad Dermatol 2000;43:S51-4
64. Bershad S, Kranjac Singer G, Parente JE. Successful treatment of acne vulgaris using a new method. Results of a randomized vehicle-controlled trial of short-contact therapy with 0.1% tazarotene gel. Arch Dermatol 2002;138:481-489
65. th Annual Meeting of the American Academy of Dermatology, March 10-15, 2000, San Francisco, CA
66. Leyden J. Meta-analysis of topical tazarotene in the treatment of mild to moderate acne. Cutis 2004;74(Suppl 4):4-8 (Pubitemid 39462883)
67. Leyden J, Lowe N, Kakita L, Draelos Z. Comparison of treatment of acne vulgaris with alternate-day applications of tazarotene 0.1% gel and once-daily applications of adapalene 0.1% gel: a randomized trial. Cutis 2001;67:10-16
68. Gold LS, Colón LE, Johnson LA, Gottschalk RW. Is switching retinoids a sound strategy for the treatment of acne vulgaris? J Drugs Dermatol 2008;7(6):11-17
69. Leyden J, Thiboutot DM, Shalita AR, et al. Comparison of Tazarotene and Minocycline Maintenance Therapies in Acne Vulgaris: A Multicenter, Double-blinded, Randomized, Parallel- Group Study. Arch Dermatol 2006;142:605-612 (Pubitemid 43727551)
70. Gilchrest BA. A review of skin aging and its medical therapy. Br J Dermatol 1996;135:867-875 (Pubitemid 26397913)
71. Mukherjee S, Date A, Patravale V, et al. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin Int Aging 2006;1(4):327-348
72. Kang S, Fisher GJ, Voorhees JJ. Photoaging: Pathogenesis, prevention, and treatment. Clin Ger Med 2001;17:643-659
73. Lavker RM, Klingman AM. Chronic heliodermatitis: a morphologic ealuation of chronic dermal damage with emphasis on the role of mast cells. J Invest Dermatol 1988;266:17662-17666
74. Rittié L, Fisher GJ. UV-light-induced signal cascades and skin aging. Aging Res Rev 2002;1:705-720 (Pubitemid 38344146)
75. Massague J. TGF-β signal transduction. Ann Rev Biochem 1998;67:753-791
76. Griffiths CE. Dowling Oration delivered at the Royal College of Physicians, London, Retinoids: renaissance and reformation. Clin Exp Dermatol 1998;24:329-335
77. Nagpal S, Athanikar J, Chandraratna RA. Separation of transactivation and AP1 antagonism functions of retinoid acid receptor alpha. J Biol Chem 1995;270:923-927
78. Chandraratna RA. Tazarotene - first of a new generation of receptor - selective retinoids. Br J Dermatol 1996;135(49):18-25 (Pubitemid 126833473)
79. Machtinger LA, Kaidbey K, Lim J, et al. Histological effects of tazarotene 0.1% cream vs. vehicle on photodamaged skin: a 6-month, milticentre, double-blind, randomized, vehicle-controlled study in patients with photodamaged facial skin. Br J Dermatol 2004;151:1245-1252 (Pubitemid 40030173)
80. Kang S, Krueger GG, Tanghetti EA. A multicenter, randomized, double-blind trial of tazarotene 0.1% cream in the treatment of photodamage. J Am Acad Dermatol 2005;52(2):268-274
81. Phillips TJ, Gottlieb AB, Leyden JJ, et al. Efficacy of 0.1% Tazarotene Cream for the Treatment of Photodamage: A 12-Month Multicenter, Randomized Trial. Arch Dermatol 2002;138:1486-1493 (Pubitemid 35315739)
82. Kang S, Leyden JJ, Lowe NJ, et al. Tazarotene Cream for the Treatment of Facial Photodamage: a multicenter, investigator-masked, randomized, vehicle-controlled, parallel comparison of 0.01%, 0.025%, 0.05%, and 0.1% tazarotene creams with 0.05% tretinoin emollient cream applied once daily for 24 weeks. Arch Dermatol 2001;137:1597-1604
83. Lowe N, Gifford M, Tanghetti E, et al. Tazarotene 0.1% cream versus tretinoin 0.05% emollient cream in the treatment of photodamaged facial skin: a multicenter, double-blind, randomized, parallel-group study. J Cosmet Laser Ther 2004;6:79-85 (Pubitemid 38980532)
84. Lowe N, Horwitz S, Tanghetti E, et al. Tazarotene versus tazarotene plus hydroquinone in the treatment of photodamaged facial skin: a multicenter, double-blind, randomized study. J Cosmet Laser Ther 2006;8:121-127 (Pubitemid 44395592)
85. Taylor S. Tazarotene in the treatment of pseudofolliculitis barbae in patients with skin color: an investigator masked, split-face, placebo controlled, parallel group study. Poster presented at: American Academy of Dermatology Summer Meeting; July 31 - August 4, 2002; New York. p. 26
86. th Annual meeting of the American Academy of Dermatology; Feburary 22-27, 2002; New Orleans, LA. p. 190
87. Weisshar E, Bonnekoh B, Franke I, et al. Successful symptomatic tazarotene of juvenile acanthosis nigricans of the familial obesity-associated type in insulin resistance. Hautarzt 2001;52:499-503 (Pubitemid 32510362)
88. Grimes P, Callender V. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a double-blind, randomized, vehicle-controlled study. Cutis 2006;77(1):45-50 (Pubitemid 43189155)
89. Patterson WM, Fox MD, Schwartz RA. Favre-Racouchot Disease. Int J Dermatol 2004;43:167-169
90. Rallis E, Karanikola E, Verros C. Successful treatment of Favre-Racouchot Disease with 0.05% tazarotene gel. Arch Dermatol 2007;143:810-812 (Pubitemid 46955761)
91. Gerbig AW. Treating keratosis pilaris. J Am Acad Dermatol 2002;47(3):457
92. Nguyen V, Cunningham B, Eichenfield L, et al. Treatment of ichthosiform diseases with topically applied tazarotene: risk of systemic absorption. J Am Acad Dermatol 2006:57(5):S123-4
93. Yoo S, Simzar S, Han K, et al. Erythrokeratoderma variabilis successfully treated with topical tazarotene. Pediatr Dermatol 2006;23(4):382-385 (Pubitemid 44199431)
94. Wolbach SB, Howe PR. Tissue changes following deprivation of fat soluble A vitamin. J Exp Med 1925;43:753
95. Teherani DK, Parissa M, Tanwew A. Response of juvenile circumscribed pityriasis rubra pilaris to topical tazarotene treatment. Ped Dermatol 2008;25:125-126 (Pubitemid 351315473)
96. Naineni KK, Hohle R, Lucke T. Disseminated superficial actinic porokeratosis of the scalp. Clin Exp Dermatol 2007;32(2):222-223 (Pubitemid 46233044)
97. Rand R, Baden HP. Commentary: Darier-White disease. Arch Dermatol 1983;119:81-83
98. Itin PH, Büchner SA, Happle R. Segmental manifestation of Darier disease. Dermatol 2000;200:254-257
99. Burkhart CG, Burkhart CN. Tazarotene gel for Darier's disease. J Am Acad Dermatol 1998;38:1001-1002 (Pubitemid 28299202)
100. Oster-Schmidt . The treatment of Darier's disease with topical tazarotene. Br J Dermatol 1999;141:603-604 (Pubitemid 29448456)
101. Micali G, Nasca MR. Tazarotene gel in childhood Darier disease. Pediatr Dermatol 1999;16:243-244 (Pubitemid 29270217)
102. Brazzelli V, Prestinari F, Barbagallo T, et al. Linear Darier's disease successfully treated with 0.1% tazarotene gel "short-contact" therapy. Eur J Dermatol 2006;16(1):59-61
103. Apisarnthanarax N, Talpur R, Ward S, et al. Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study. J Am Acad Dermatol 2004;50(4):600-607 (Pubitemid 38393171)
104. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002;146(61):1-6 (Pubitemid 34437802)
105. Marghoob AA. Basal and squamous cell carcinomas: what every primary care physician should know. Postgrad Med 1997;102:139-159 (Pubitemid 27353755)
106. Vine JE. Skin cancer update. Treatment alternatives for basal-cell and squamous-cell carcinoma. N J Med 2001;98:35-37
107. Bianchi L, Orlandi A, Campione E, et al. Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases. Br J Dermatol 2004;151(1):148-156 (Pubitemid 39061292)
108. Bardazzi F, Bianchi F, Parente G, et al. A pilot study on the use of topical tazarotene to treat squamous cell carcinoma in situ. J Am Acad Dermatol 2005;52(6):1102-1104 (Pubitemid 40732561)
109. Ofmann B, Stege H, Ruzicka T, Lehmann P. Effect of topical tazarotene in the treatment of congenital ichthyoses. Br J Dermatol 1999;141:642-646 (Pubitemid 29512816)
110. Pedersen NB. Persistent occupational koilonychia. Contact Dermatitis 1982;8:134
111. Scher RK, Stiller M, Zhu YI. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study. Cutis 2001;68:355-358 (Pubitemid 33756739)
112. Bianchi L, Soda R, Diluvio L, Chimenti S. Tazarotene 0.1% gel in finger and toenail psoriasis: a prospective open study. Br J Dermatol 2003;149(1):207-209 (Pubitemid 36966543)
113. Hagman JH, Ginebri A, Mordenti C, et al. Treatment of Occupational Koilonychia with Tazarotene Gel. Acta Derm Venereol 2003;83:296-297 (Pubitemid 36920609)
114. Koo J, Behnam SE, Behnam SM. The efficacy of topical tazarotene montherapy and combination therapies in psoriasis. Expert Opin Pharmacothe 2003;4(12):2347-2354 (Pubitemid 37541246)
115. Menter A. Pharmacokinetics and safety of tazarotene. J Am Acad Dermatol 2000;43:S31-S35
116. Available from: http://www.drugs.com/pro/tazorac.html. Tazorac Gel package insert (Allergan Herbert-US), Rev 6/97, Rec 6/97
117. Life Science. Allergan psoriasis treatment tazarotene denied approval by FDA. Available from: www.newsrx.com/newsletters/Life-Science-Weekly. [Accessed 31 October 2008]
118. van de Kerkhof PC. Update on retinoid therapy of psoriasis in: an update on the use of retinoids in dermatology. Dermatol Ther 2006;19(5):252-263 (Pubitemid 44470109)